toxification · Mechanism Report

Is urinary N-acetyl-S-(3,4-dihydroxybutyl)-L-cysteine a biomarker of 1,3-butadiene exposure?

Urinary N-acetyl-S-(3,4-dihydroxybutyl)-L-cysteine is a well-supported biomarker of 1,3-butadiene exposure and metabolism.

PlausibleSeptember 22, 20269 Sources

This is what AI claimed

Urinary N-acetyl-S-(3,4-dihydroxybutyl)-L-cysteine is a mercapturic-acid biomarker of 1,3-butadiene exposure, reflecting glutathione conjugation and urinary elimination.

1 of 3 paths supported

Executive summary

The claim says this urinary mercapturic acid reflects 1,3-butadiene uptake through glutathione-linked metabolism and subsequent urinary elimination. The mechanism framing shows an oxidized butadiene intermediate progressing through detoxification steps that produce the biomarker. It also indicates that the marker is useful for exposure assessment rather than as a direct disease marker.

Verified conclusion

1,3-Butadiene is metabolically activated and detoxified through pathways that yield urinary mercapturates. In this context, urinary N-acetyl-S-(3,4-dihydroxybutyl)-L-cysteine—DHBMA or 34HBMA—is a well-supported biomarker of butadiene uptake and metabolism, not a marker of disease or toxicity.

Clinical and exposure-biomonitoring evidence

DHBMA is the predominant urinary mercapturic acid associated with 1,3-butadiene in humans, reported to account for roughly 93–97% or more of urinary butadiene-associated mercapturates.
Urinary DHBMA rises with occupational butadiene exposure and correlates with butadiene–hemoglobin biomarkers, supporting its use in exposure assessment.
Its apparent urinary half-life in occupational biomonitoring is approximately 10–11 hours. Results are therefore particularly sensitive to timing; end-of-shift collection, creatinine normalization, smoking history, and concurrent air measurements improve interpretation.
DHBMA is measurable in smokers and nonsmokers, with substantial endogenous/background formation. An isolated low-level elevation cannot reliably identify the exposure source, quantify an individual’s dose, or distinguish smoking-related from other exposure.

Mechanistic basis

CYP-mediated metabolism, including CYP2E1/CYP2A6, oxidizes butadiene to 3,4-epoxy-1-butene (butadiene monoepoxide).
Epoxide hydrolase predominantly converts this epoxide to 1,2-dihydroxy-3-butene. Glutathione conjugation of the diol-derived intermediate, followed by mercapturic-acid processing—removal of glutamate and glycine residues and N-acetylation—produces DHBMA for urinary elimination.
A parallel direct glutathione-conjugation route from monoepoxide yields MHBMA isomers. Measuring MHBMA with DHBMA may strengthen evidence for recent exogenous butadiene exposure because MHBMA is less abundant but more specific.

Bottom line

Urinary DHBMA credibly reflects glutathione-derived mercapturic-acid metabolism and urinary elimination after 1,3-butadiene exposure, but interpretation requires exposure context because background formation limits specificity at low concentrations.

References

See a full patient report verified like this

Book a walkthrough

Executive summary

Verified conclusion

Clinical and exposure-biomonitoring evidence

DHBMA is the predominant urinary mercapturic acid associated with 1,3-butadiene in humans, reported to account for roughly 93–97% or more of urinary butadiene-associated mercapturates.
Urinary DHBMA rises with occupational butadiene exposure and correlates with butadiene–hemoglobin biomarkers, supporting its use in exposure assessment.
Its apparent urinary half-life in occupational biomonitoring is approximately 10–11 hours. Results are therefore particularly sensitive to timing; end-of-shift collection, creatinine normalization, smoking history, and concurrent air measurements improve interpretation.
DHBMA is measurable in smokers and nonsmokers, with substantial endogenous/background formation. An isolated low-level elevation cannot reliably identify the exposure source, quantify an individual’s dose, or distinguish smoking-related from other exposure.

Mechanistic basis

CYP-mediated metabolism, including CYP2E1/CYP2A6, oxidizes butadiene to 3,4-epoxy-1-butene (butadiene monoepoxide).
Epoxide hydrolase predominantly converts this epoxide to 1,2-dihydroxy-3-butene. Glutathione conjugation of the diol-derived intermediate, followed by mercapturic-acid processing—removal of glutamate and glycine residues and N-acetylation—produces DHBMA for urinary elimination.
A parallel direct glutathione-conjugation route from monoepoxide yields MHBMA isomers. Measuring MHBMA with DHBMA may strengthen evidence for recent exogenous butadiene exposure because MHBMA is less abundant but more specific.

Bottom line

Urinary DHBMA credibly reflects glutathione-derived mercapturic-acid metabolism and urinary elimination after 1,3-butadiene exposure, but interpretation requires exposure context because background formation limits specificity at low concentrations.